// App-Quantinova.ai

P1-01-01 : Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial

Researchers

Presenter

  • C Paoletti

Principal Investigators

  • MC Liu

  • PK Marcom

  • LL Hart

  • JW Smith, II

  • KL Tedesco

  • E Amir

  • IE Krop

  • AM DeMichele

  • PJ Goodwin

  • M Block

  • K Aung

  • EM Cannell

  • EP Darga

  • PJ Baratta

  • ME Brown

  • RT McCormack

  • DF Hayes

Medical Centers

  • Northwest Cancer Specialists, Portland, OR

  • Florida Cancer Specialist South Division, Fort Myers, FL

  • Duke University, Duke Cancer Center, Durham, NC

  • Dana-Farber Cancer Institute, Boston, MA

  • University of Pennsylvania, Philadelphia, PA

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Nebraska Cancer Specialists, Omaha, NE

  • Mt. Sinai Hospital-Toronto, Toronto, ON, Canada

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Mayo Clinic, Rochester, MN

  • New York Oncology Hematology, US Oncology, Albany, NY

Locations

  • United States

  • Canada

Companies

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • B-cell lymphoma 2

  • Circulating tumor cells

  • Proliferation marker protein Ki-67

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • pharmacokinetics

Phase

  • II

Study Id's

  • NCT01701050

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved